Preliminary study on effect of high dose of Andrographis paniculata extract capsule in mild COVID-19 patients

Phase 1

Completed

• Registration Number: TCTR20210914001
• Lead Sponsor: Thai Traditional Medicine Knowlegde funding

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2020-07-14
• Study Start: 2021-09-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

1) age 18 to 60 years 2) diagnosis of SARS-CoV-2 infection by positive rRT-PCR test 3) being admitted to hospital within 72 hours of illness 4) presence of any signs and symptoms of mild COVID-19 (e.g., fever, cough, sore throat, malaise, headache, and diarrhea) 5) not having signs and symptoms of pneumonia or abnormal chest imaging

Exclusion Criteria

1) Patient who be treated with any antiviral drugs i.e. favipiravir, remdesivir, Lopinavir, ritonavir, interferon (b1a), chloroquine or hydroxychloroquine 2) History of allergy to A. paniculata 3) Pregnancy or during lactation 4) Patient who has underlying medical conditions that increase risk of severe COVID-19 5) Patient with history of rheumatic heart disease and/or renal dysfunction due to Streptococcus group A 6) Patient who be treated with anticoagulants i.e., clopidogrel, warfarin, and aspirin.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
symptom severity 5 days visual anolog scale,Adverse event 5 days number and severity of event

Secondary Outcome Measures

Name	Time	Method
Inflamatory cytokines 5 days Bio-plex assay,metabolite profile 5 days LC-MS,viral load 5 days rt-pcr ct value calculation